Status:
COMPLETED
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Epilepsies, Partial
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current med...
Eligibility Criteria
Inclusion
- Epilepsy partial seizure subjects.
- Currently taking 1 to 3 antiepileptic drugs.
Exclusion
- Pre-existing eye diseases (glaucoma).
- Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.
Key Trial Info
Start Date :
July 26 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2020
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT00351611
Start Date
July 26 2006
End Date
February 4 2020
Last Update
April 13 2021
Active Locations (150)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology Center, P.C.
Mobile, Alabama, United States, 36607
2
Premier Medical Group
Mobile, Alabama, United States, 36608
3
Neurology Clinic, PC
Northport, Alabama, United States, 35476
4
North River Ophthalmology
Tuscaloosa, Alabama, United States, 35406